Patents by Inventor Jeffrey Greiwe

Jeffrey Greiwe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tranexamic acid formulations with reduced adverse effects
    Publication number: 20060127476
    Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
    Type: Application
    Filed: February 3, 2006
    Publication date: June 15, 2006
    Applicant: Xanodyne Pharmaceuticals, Inc.
    Inventors: Ralph Heasley, Keith Moore, Jeffrey Greiwe
  • Tranexamic acid formulations
    Publication number: 20050245614
    Abstract: Disclosed are oral tranexamic acid formulations and methods of treatment therewith.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 3, 2005
    Applicant: Xanodyne Pharmaceuticals, Inc.
    Inventors: Keith Moore, Ralph Heasley, Jeffrey Greiwe
  • Tranexamic acid formulations
    Publication number: 20050244495
    Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 3, 2005
    Applicant: Xanodyne Pharmaceuticals, Inc.
    Inventors: Keith Moore, Ralph Heasley, Jeffrey Greiwe
  • Tranexamic acid formulations with reduced adverse effects
    Publication number: 20050025825
    Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
    Type: Application
    Filed: July 31, 2003
    Publication date: February 3, 2005
    Applicant: Xanodyne Pharmacal, Inc.
    Inventors: Ralph Heasley, Keith Moore, Jeffrey Greiwe